Chandni Radhakrishnan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Chandni Radhakrishnan has a total of 272 co-authors. Here are the top co-authors by number of shared publications:
- Govindakarnavar Arunkumar
World Health Organization Country Office for Nepal, Kathmandu, Nepal
4 shared publications Nivedita Gupta
Indian Council of Medical Research, Ansari Nagar, New Delhi, India
3 shared publications- Pragya Dhruv Yadav
ICMR-National Institute of Virology, Pune, India
3 shared publications Raman R. Gangakhedkar
Indian Council of Medical Research, Ansari Nagar, New Delhi, India
3 shared publicationsAnita M. Shete
ICMR-National Institute of Virology, Microbial Containment Complex, Sus-Pashan Road, Pune, Maharashtra, India
2 shared publications- Anup Jayaram
Manipal Institute of Virology Manipal Academy of Higher Education, Manipal Udupi Karnataka India
2 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Evaluating Vaccine Efficacy During Outbreaks and Emerging Infections: Opportunities for Innovation
The Coalition for Epidemic Preparedness Innovations’ (CEPI) 100 Days Mission, and broader global pandemic preparedness efforts, require overcoming challenges in evaluating vaccine efficacy during emerging epidemics and outbreaks. Key challenges, addressed in a workshop jointly hosted by CEPI and the University of Oxford’s Pandemic Sciences Institute, arise from the sporadic and heterogeneous nature of outbreaks, high fatality rates that may preclude traditional placebo-controlled trials and biases from small or real-world studies. Here, we review recent developments, potential solutions and areas for innovation emphasized in the workshop to address these challenges. These opportunities for research and methodological development encompass four main areas: serology, exposure measurements, statistical modelling and trial design.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEvaluating Vaccine Efficacy During Outbreaks and Emerging Infections: Opportunities for Innovation
The Coalition for Epidemic Preparedness Innovations’ (CEPI) 100 Days Mission, and broader global pandemic preparedness efforts, require overcoming challenges in evaluating vaccine efficacy during emerging epidemics and outbreaks. Key challenges, addressed in a workshop jointly hosted by CEPI and the University of Oxford’s Pandemic Sciences Institute, arise from the sporadic and heterogeneous nature of outbreaks, high fatality rates that may preclude traditional placebo-controlled trials and biases from small or real-world studies. Here, we review recent developments, potential solutions and areas for innovation emphasized in the workshop to address these challenges. These opportunities for research and methodological development encompass four main areas: serology, exposure measurements, statistical modelling and trial design.
- Open Access
- 9 July 2026
- Published by Wolters Kluwer Health in Turkish Journal of Emergency Medicine
- Vol. 26 (3) , 217-222
Ultrasound-guided fascia iliaca compartment block for pain control in peritrochanteric fractures in the emergency department: A prospective observational study
OBJECTIVE: Hip fractures are associated with moderate-to-severe pain, which is frequently managed inadequately in emergency departments (EDs). This study set out to evaluate the analgesic effectiveness of an ultrasound-guided fascia iliaca compartment block (FIB) administered by emergency physicians to patients with peritrochanteric hip fractures. METHODS: A prospective observational study was conducted on 142 patients presenting to the ED with peritrochanteric hip fractures and a baseline Visual Analog Scale (VAS) score of 4 or higher. An ultrasound-guided FIB was performed, and pain scores were assessed at baseline, 1, 2, and 6 h. The primary outcome was ≥ 50% reduction in VAS. The secondary outcomes included need for rescue analgesia (intravenous fentanyl 1 μg/kg) and adverse events. Data were nonnormally distributed and analyzed using the Friedman test with Bonferroni-adjusted pairwise comparisons. Effect size and 95% confidence intervals (CIs) were calculated. RESULTS: The median VAS decreased from 7 (interquartile range [IQR]: 6–8) at baseline to 3 (IQR: 2–3) at 1 h, 2 (IQR: 1–2) at 2 h, and 1 (IQR: 1–2) at 6 h ( P < 0.001, Friedman test; effect size r = 0.83). A successful block (≥50% VAS reduction) was achieved in 97.2% of patients (95% CI: 92.9%–99.1%). Only 4 (2.8%) patients required rescue fentanyl. No complications, including local anesthetic systemic toxicity or delirium, were recorded. CONCLUSION: Ultrasound-guided FIB administered by trained emergency physicians is associated with significant and sustained analgesia in patients with peritrochanteric hip fractures, with minimal need for rescue opioids and no observed adverse events.
- 9 July 2026
- Published by Wolters Kluwer Health in Turkish Journal of Emergency Medicine
- Vol. 26 (3) , 217-222
Open AccessUltrasound-guided fascia iliaca compartment block for pain control in peritrochanteric fractures in the emergency department: A prospective observational study
OBJECTIVE: Hip fractures are associated with moderate-to-severe pain, which is frequently managed inadequately in emergency departments (EDs). This study set out to evaluate the analgesic effectiveness of an ultrasound-guided fascia iliaca compartment block (FIB) administered by emergency physicians to patients with peritrochanteric hip fractures. METHODS: A prospective observational study was conducted on 142 patients presenting to the ED with peritrochanteric hip fractures and a baseline Visual Analog Scale (VAS) score of 4 or higher. An ultrasound-guided FIB was performed, and pain scores were assessed at baseline, 1, 2, and 6 h. The primary outcome was ≥ 50% reduction in VAS. The secondary outcomes included need for rescue analgesia (intravenous fentanyl 1 μg/kg) and adverse events. Data were nonnormally distributed and analyzed using the Friedman test with Bonferroni-adjusted pairwise comparisons. Effect size and 95% confidence intervals (CIs) were calculated. RESULTS: The median VAS decreased from 7 (interquartile range [IQR]: 6–8) at baseline to 3 (IQR: 2–3) at 1 h, 2 (IQR: 1–2) at 2 h, and 1 (IQR: 1–2) at 6 h ( P < 0.001, Friedman test; effect size r = 0.83). A successful block (≥50% VAS reduction) was achieved in 97.2% of patients (95% CI: 92.9%–99.1%). Only 4 (2.8%) patients required rescue fentanyl. No complications, including local anesthetic systemic toxicity or delirium, were recorded. CONCLUSION: Ultrasound-guided FIB administered by trained emergency physicians is associated with significant and sustained analgesia in patients with peritrochanteric hip fractures, with minimal need for rescue opioids and no observed adverse events.
- Open Access
- 10 March 2026
- Published by Elsevier in SSRN Electronic Journal
Methodological Framework and Socio-Demographic Variation in the Pan-Indian Mixed-Method Study of Type 2 Diabetes Adults
Background: Type 2 diabetes mellitus (T2DM) affects over 100 million adults in India, yet regional socio-demographic variability and lifestyle patterns remain underexplored. Existing national guidelines largely adopt a “one-size-fits-all” approach, highlighting the need for contextualized, personalized strategies.Objective: To describe the socio-demographic characteristics of T2DM Indian adults across six regions, establishing a foundation for tailored lifestyle interventions and recommendations.Methods: This mixed-method multi-centric investigation involved 603 adults aged ≥ 25 years with confirmed T2DM from 18 diabetes centres across six geographic regions. A cross-sectional survey captured eight domains: socio-demographics, lifestyle factors, 24-hour dietary recall, food frequency, International Physical Activity Questionnaire–Short Form (IPAQ-SF), food choices, eating behaviour, and Knowledge, Attitude, Practices (KAP). Three validated instruments (24-hour recall, FFQ, IPAQ-SF) were supplemented with study-specific questions. Systematic random sampling (every 5th patient) was employed with informed consent. In-depth interviews were conducted with clinicians and T2DM adults to capture lived experiences, using audio recordings in English, Hindi, or regional languages with translation support when necessary. Quantitative data were analysed using descriptive statistics (Excel) and inferential analyses (SPSS). Multivariable linear regression models were used to address confounding across more than 100 variables (SPSS). Qualitative data were thematically analysed.Results: Socio-demographic patterns revealed substantial variability in age, urban-rural residence, education, family structure, and income levels. The majority of participants were middle-aged, married, and lived in nuclear families. Urban predominance, higher education, and higher income were observed in some regions, whereas others exhibited greater rural representation and lower socioeconomic status. Gender distribution was largely balanced. Heat maps were used to visualise inter-regional differences in socio-demographic indicators.Conclusions: This study provides the first comprehensive, regionally diverse assessment of socio-demographic characteristics among adults with T2DM in India. Findings highlight the importance of culturally and contextually tailored interventions and form a foundation for designing region-sensitive diabetes prevention and management strategies.
- 10 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMethodological Framework and Socio-Demographic Variation in the Pan-Indian Mixed-Method Study of Type 2 Diabetes Adults
Background: Type 2 diabetes mellitus (T2DM) affects over 100 million adults in India, yet regional socio-demographic variability and lifestyle patterns remain underexplored. Existing national guidelines largely adopt a “one-size-fits-all” approach, highlighting the need for contextualized, personalized strategies.Objective: To describe the socio-demographic characteristics of T2DM Indian adults across six regions, establishing a foundation for tailored lifestyle interventions and recommendations.Methods: This mixed-method multi-centric investigation involved 603 adults aged ≥ 25 years with confirmed T2DM from 18 diabetes centres across six geographic regions. A cross-sectional survey captured eight domains: socio-demographics, lifestyle factors, 24-hour dietary recall, food frequency, International Physical Activity Questionnaire–Short Form (IPAQ-SF), food choices, eating behaviour, and Knowledge, Attitude, Practices (KAP). Three validated instruments (24-hour recall, FFQ, IPAQ-SF) were supplemented with study-specific questions. Systematic random sampling (every 5th patient) was employed with informed consent. In-depth interviews were conducted with clinicians and T2DM adults to capture lived experiences, using audio recordings in English, Hindi, or regional languages with translation support when necessary. Quantitative data were analysed using descriptive statistics (Excel) and inferential analyses (SPSS). Multivariable linear regression models were used to address confounding across more than 100 variables (SPSS). Qualitative data were thematically analysed.Results: Socio-demographic patterns revealed substantial variability in age, urban-rural residence, education, family structure, and income levels. The majority of participants were middle-aged, married, and lived in nuclear families. Urban predominance, higher education, and higher income were observed in some regions, whereas others exhibited greater rural representation and lower socioeconomic status. Gender distribution was largely balanced. Heat maps were used to visualise inter-regional differences in socio-demographic indicators.Conclusions: This study provides the first comprehensive, regionally diverse assessment of socio-demographic characteristics among adults with T2DM in India. Findings highlight the importance of culturally and contextually tailored interventions and form a foundation for designing region-sensitive diabetes prevention and management strategies.
- Open Access
- 27 January 2026
- Published by Springer Nature in Cureus
- Vol. 18 (1)
Clinical Spectrum and Outcomes of Melioidosis: An Eight-Year Study
- 27 January 2026
- Published by Springer Nature in Cureus
- Vol. 18 (1)
Open AccessClinical Spectrum and Outcomes of Melioidosis: An Eight-Year Study
- 2 June 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 226, 112289
Profile of monogenic diabetes: a Pan-India study
- 2 June 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 226, 112289
Profile of monogenic diabetes: a Pan-India study
- Open Access
- 4 June 2024
- Published by Springer Nature in Cureus
- Vol. 16 (6)
Temporal Trends in SARS-CoV-2 Antibody Levels Among COVID-19 Patients in Kerala During the First Wave and Pre-vaccination Period
Background: The SARS-CoV-2 virus interacts with host cells through the S1 domain of its spike protein. This study measures the IgG immune response to this domain in COVID-19 patients from Kerala, India, and explores its association with various health factors. Methods: A cohort of 258 COVID-19 patients was analyzed for IgG antibodies targeting the S1 spike protein domain. The temporal pattern of the IgG response and its correlation with hospitalization needs, intensive care, and pre-existing conditions such as diabetes, hypertension, and coronary artery disease were assessed. Results: A significant IgG response (76.4%) was detected, indicating robust immune activation post-infection. The IgG levels peaked between two to four and four to eight weeks post-infection, with a notable increase at 12 weeks, hinting at possible secondary exposure or an immune memory response. No correlation was found between IgG levels and the presence of diabetes mellitus, hypertension, or coronary artery disease. However, higher IgG responses correlated with the severity of the infection, as seen in patients requiring hospitalization or intensive care. Conclusions: The IgG response to the S1 spike protein domain serves as a potential marker of immune activation in COVID-19. It reflects the body’s defense mechanism against the virus and may predict disease severity and outcomes. The findings suggest that IgG levels could be indicative of the viral load, inflammatory response, and possibly the likelihood of protection against reinfection.
- 4 June 2024
- Published by Springer Nature in Cureus
- Vol. 16 (6)
Open AccessTemporal Trends in SARS-CoV-2 Antibody Levels Among COVID-19 Patients in Kerala During the First Wave and Pre-vaccination Period
Background: The SARS-CoV-2 virus interacts with host cells through the S1 domain of its spike protein. This study measures the IgG immune response to this domain in COVID-19 patients from Kerala, India, and explores its association with various health factors. Methods: A cohort of 258 COVID-19 patients was analyzed for IgG antibodies targeting the S1 spike protein domain. The temporal pattern of the IgG response and its correlation with hospitalization needs, intensive care, and pre-existing conditions such as diabetes, hypertension, and coronary artery disease were assessed. Results: A significant IgG response (76.4%) was detected, indicating robust immune activation post-infection. The IgG levels peaked between two to four and four to eight weeks post-infection, with a notable increase at 12 weeks, hinting at possible secondary exposure or an immune memory response. No correlation was found between IgG levels and the presence of diabetes mellitus, hypertension, or coronary artery disease. However, higher IgG responses correlated with the severity of the infection, as seen in patients requiring hospitalization or intensive care. Conclusions: The IgG response to the S1 spike protein domain serves as a potential marker of immune activation in COVID-19. It reflects the body’s defense mechanism against the virus and may predict disease severity and outcomes. The findings suggest that IgG levels could be indicative of the viral load, inflammatory response, and possibly the likelihood of protection against reinfection.
- Open Access
- 25 August 2022
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 10, 974667
Genomic surveillance of SARS-CoV-2 by sequencing the RBD region using Sanger sequencing from North Kerala
Next Generation Sequencing (NGS) is the gold standard for the detection of new variants of SARS-CoV-2 including those which have immune escape properties, high infectivity, and variable severity. This test is helpful in genomic surveillance, for planning appropriate and timely public health interventions. But labs with NGS facilities are not available in small or medium research settings due to the high cost of setting up such a facility. Transportation of samples from many places to few centers for NGS testing also produces delays due to transportation and sample overload leading in turn to delays in patient management and community interventions. This becomes more important for patients traveling from hotspot regions or those suspected of harboring a new variant. Another major issue is the high cost of NGS-based tests. Thus, it may not be a good option for an economically viable surveillance program requiring immediate result generation and patient follow-up. The current study used a cost-effective facility which can be set up in a common research lab and which is replicable in similar centers with expertise in Sanger nucleotide sequencing. More samples can be processed at a time and can generate the results in a maximum of 2 days (1 day for a 24 h working lab). We analyzed the nucleotide sequence of the Receptor Binding Domain (RBD) region of SARS-CoV-2 by the Sanger sequencing using in-house developed methods. The SARS-CoV-2 variant surveillance was done during the period of March 2021 to May 2022 in the Northern region of Kerala, a state in India with a population of 36.4 million, for implementing appropriate timely interventions. Our findings broadly agree with those from elsewhere in India and other countries during the period.
- 25 August 2022
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 10, 974667
Open AccessGenomic surveillance of SARS-CoV-2 by sequencing the RBD region using Sanger sequencing from North Kerala
Next Generation Sequencing (NGS) is the gold standard for the detection of new variants of SARS-CoV-2 including those which have immune escape properties, high infectivity, and variable severity. This test is helpful in genomic surveillance, for planning appropriate and timely public health interventions. But labs with NGS facilities are not available in small or medium research settings due to the high cost of setting up such a facility. Transportation of samples from many places to few centers for NGS testing also produces delays due to transportation and sample overload leading in turn to delays in patient management and community interventions. This becomes more important for patients traveling from hotspot regions or those suspected of harboring a new variant. Another major issue is the high cost of NGS-based tests. Thus, it may not be a good option for an economically viable surveillance program requiring immediate result generation and patient follow-up. The current study used a cost-effective facility which can be set up in a common research lab and which is replicable in similar centers with expertise in Sanger nucleotide sequencing. More samples can be processed at a time and can generate the results in a maximum of 2 days (1 day for a 24 h working lab). We analyzed the nucleotide sequence of the Receptor Binding Domain (RBD) region of SARS-CoV-2 by the Sanger sequencing using in-house developed methods. The SARS-CoV-2 variant surveillance was done during the period of March 2021 to May 2022 in the Northern region of Kerala, a state in India with a population of 36.4 million, for implementing appropriate timely interventions. Our findings broadly agree with those from elsewhere in India and other countries during the period.
- 1 August 2021
- Published by Elsevier in Journal of Infection
- Vol. 83 (2) , 237-279
Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India
- 1 August 2021
- Published by Elsevier in Journal of Infection
- Vol. 83 (2) , 237-279
Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India
- 8 June 2021
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 16 (2) , 217-232
Efficacy and Cardiovascular Safety of Insulins
: Insulin is a lifesaving drug for patients with type 1 diabetes mellitus. Many type 2 diabetes mellitus patients will eventually require insulin. The rapid-acting and long-acting insulin analogues (RAIAs and LAIAs) have a pharmacological profile that closely mimics normal human physiology when compared to Neutral Protamine Hagedorn (NPH) insulin and regular human insulin, respectively. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) were found to have a proven cardiovascular safety. They are preferred over insulin in many recent guidelines. Fixed-ratio combinations of GLP-1RAs and insulin are also recommended when either of these molecules fail to achieve glycaemic control. Despite decades of experience in using insulin, there is a debate among the scientific community over the safety of exogenous insulin, especially regarding their cardiovascular safety and the risk of cancer. There is also an ongoing debate regarding the safety, even though two long-acting insulin analogues (glargine and degludec) have proven their cardiovascular non-inferiority. Drugs with proven safety are often preferred in patients with pre-existing cardiovascular disease or at high risk of cardiovascular disease. In this review we will critically analyse efficacy and safety issues related to insulin molecules to help in clinical decision making.
- 8 June 2021
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 16 (2) , 217-232
Efficacy and Cardiovascular Safety of Insulins
: Insulin is a lifesaving drug for patients with type 1 diabetes mellitus. Many type 2 diabetes mellitus patients will eventually require insulin. The rapid-acting and long-acting insulin analogues (RAIAs and LAIAs) have a pharmacological profile that closely mimics normal human physiology when compared to Neutral Protamine Hagedorn (NPH) insulin and regular human insulin, respectively. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) were found to have a proven cardiovascular safety. They are preferred over insulin in many recent guidelines. Fixed-ratio combinations of GLP-1RAs and insulin are also recommended when either of these molecules fail to achieve glycaemic control. Despite decades of experience in using insulin, there is a debate among the scientific community over the safety of exogenous insulin, especially regarding their cardiovascular safety and the risk of cancer. There is also an ongoing debate regarding the safety, even though two long-acting insulin analogues (glargine and degludec) have proven their cardiovascular non-inferiority. Drugs with proven safety are often preferred in patients with pre-existing cardiovascular disease or at high risk of cardiovascular disease. In this review we will critically analyse efficacy and safety issues related to insulin molecules to help in clinical decision making.
- Open Access
- 23 April 2020
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 148, e90
Experiential learnings from the Nipah virus outbreaks in Kerala towards containment of infectious public health emergencies in India
Nipah virus (NiV) outbreak occurred in Kozhikode district, Kerala, India in 2018 with a case fatality rate of 91% (21/23). In 2019, a single case with full recovery occurred in Ernakulam district. We described the response and control measures by the Indian Council of Medical Research and Kerala State Government for the 2019 NiV outbreak. The establishment of Point of Care assays and monoclonal antibodies administration facility for early diagnosis, response and treatment, intensified contact tracing activities, bio-risk management and hospital infection control training of healthcare workers contributed to effective control and containment of NiV outbreak in Ernakulam.
- 23 April 2020
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 148, e90
Open AccessExperiential learnings from the Nipah virus outbreaks in Kerala towards containment of infectious public health emergencies in India
Nipah virus (NiV) outbreak occurred in Kozhikode district, Kerala, India in 2018 with a case fatality rate of 91% (21/23). In 2019, a single case with full recovery occurred in Ernakulam district. We described the response and control measures by the Indian Council of Medical Research and Kerala State Government for the 2019 NiV outbreak. The establishment of Point of Care assays and monoclonal antibodies administration facility for early diagnosis, response and treatment, intensified contact tracing activities, bio-risk management and hospital infection control training of healthcare workers contributed to effective control and containment of NiV outbreak in Ernakulam.